An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Rovatirelin (Primary)
- Indications Spinocerebellar ataxias
- Focus Therapeutic Use
- Sponsors Kissei Pharmaceutical
- 15 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 11 Nov 2016 Status changed from not yet recruiting to recruiting.
- 31 Aug 2016 Status changed from planning to not yet recruiting.